And we have a long way to go before we fully understand the relationship between CBD and pain regulation. But strong anecdotal evidence, combined with multiple lab tests and even some clinical trials, have established that CBD holds a lot of promise for pain relief. Or in science-speak, CBD “represents a novel class of therapeutic agents for the treatment of chronic pain.”
Neuropathic pain: This type of pain comes from damage to your nervous system itself from injury, disease, or pinching. It tends to be chronic since nerves often don’t heal well. It may feel electrical, burning, or stabbing. Examples of neuropathic pain include sciatica or hitting your funny bone, and also any major pain caused by anything that damages your neurons such as chemotherapy, multiple sclerosis, or alcoholism.
Dispensaries: In states where marijuana is legal for recreational use, dispensaries are a common sight. They are much rarer in states with more restrictions. In states that permit the use of medical marijuana, hemp-based CBD oils do not normally require a prescription but marijuana-based oils do. Like brick-and-mortar locations, dispensaries offer more customer service. However, as noted, this may not be an option depending on the buyer’s state of residence. Also, CBD oil prices tend to be significantly higher at dispensaries.
So. According to the Controlled Substance Act definition itself, certain parts of the cannabis plant are clearly illegal, while others fall into a grayer area. One of these – for the most part – is CBD extracted from the “legal” parts of the cannabis plant, and non-marijuana industrial hemp plants, which, as defined by Section 7606 of the Farm Bill are cannabis plants with less than 0.3 percent THC.
Your product is not generally recognized as safe and effective for the referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the Act [21 U.S.C. § 355(a)]; see also section 301(d) of the Act [21 U.S.C. § 331(d)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.